title: Retroperitoneal fibrosis in a patient with Parkinson's disease treated with pergolide.
abstract: We describe a 68-year-old patient with Parkinson's disease who developed retroperitoneal fibrosis during pergolide treatment. Because pergolide is an ergot derivative, it could be related to the development of this complication.
authors.affiliation: Department of Neurology, Hospital Príncipe de Asturias, Alcalá de Henares (Madrid), Spain.
authors.forename: F J
authors.initials: FJ
authors.lastname: Jiménez-Jiménez
authors.forename: J
authors.initials: J
authors.lastname: López-Alvarez
authors.forename: M
authors.initials: M
authors.lastname: Sánchez-Chapado
authors.forename: E
authors.initials: E
authors.lastname: Montero
authors.forename: J
authors.initials: J
authors.lastname: Miquel
authors.forename: A
authors.initials: A
authors.lastname: Sierra
authors.forename: F
authors.initials: F
authors.lastname: Gutiérrez
mesh_terms: D000368:Aged; D000978:Antiparkinson Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D018491:Dopamine Agonists / Q000009:adverse effects* / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D010300:Parkinson Disease / Q000150:complications / Q000188:drug therapy*; D010479:Pergolide / Q000009:adverse effects* / Q000627:therapeutic use*; D012185:Retroperitoneal Fibrosis / Q000139:chemically induced* / Q000150:complications
chemical_list: D000978:Antiparkinson Agents; D018491:Dopamine Agonists; D010479:Pergolide